Caplin Point Laboratories Limited · NSE:CAPLIPOINT
Caplin Point Laboratories — Investor Presentation (February 2019)
17 slides from Caplin Point Laboratories's investor presentation, February 2019
Slide 1: We do things differently! Investor Presentation
We do things differently! Investor Presentation February 2019 CIN: L24231TN1990PLC019053 | BSE: 524742 | NSE: CAPLIPOINT | ISIN: INE475E01026 |DUNS:86 -148-4556 | WWW.CAPLINPOINT.NET ©2018, Caplin Point Laboratories Limited – All Rights Reserved.
Slide 2: Disclaimer
Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any i
Slide 3: Caplin Point Laboratories (CPL) at a Glance
Caplin Point Laboratories (CPL) at a Glance Covers entire spectrum of pharmaceutical 10 ANDAs filed till date with 180+ 2850+ Products formulations with 400+ products, 36 Therapeutic 3 approved and 10 more to Scientists registered Segments in 23 countries be filed by Dec 2019 in US 9M FY19 Financial
Slide 4: Business Model
Business Model Inventory turn of 9x, nearly twice the prevailing sectoral average. Efficiency Value Creation US Market Focus on growing annual topline by 15-20% and our net Strategy is a mix of profit-sharing partnerships for own ANDAs margin by 15-20%, leaving adequate value on the table for all an
Slide 5: Caplin Point Journey
Caplin Point Journey Entered challenging Consolidated leadership in Emergence of Caplin 2.0 unpenetrated markets Latin America Prior to FY 2005 FY 2006-2012 FY 2013-2018 Ventured into Angola in 1990s, Consolidated its position in Latin Marginal shift in Latin America strategy overcame challeng
Slide 6: Diversified Product Portfolio
Diversified Product Portfolio Caters to entire spectrum of pharmaceutical formulations, covering various dosage forms Total of 2,850 product licenses spread Built an end to end business with focus on bottom of the pyramid across Latin America & Africa Early adopters from Indian pharmaceutical sector
Slide 7: Research & Development Capabilities
Research & Development Capabilities Overview 5 dedicated R&D setups (3 – DSIR approved and 2 under approval) with capabilities to develop safe and effective formulations. 180+ scientists working on development of varied dosage forms such as Complex Injectables, Liposomes, Microspheres, Suspensio
Slide 8: Robust Distribution Network & Targeted Marketing
Robust Distribution Network & Targeted Marketing Work closely with pharmacists and trade intermediaries in the regions of its presence to ensure that medicines that are prescribed are in stock just when consumers need them Plant to Portal 1 Proposed extension from product manufacture to retail inter
Slide 9: Emerging Markets - Driving Growth and Profitability of Business
Emerging Markets - Driving Growth and Profitability of Business Overview Strategic Focus No. 1 Indian player in Central America Enlarging focus from Central America to mainland South Invested ~ Rs.380 crore in Capex and Opex in the last 5 American countries such as Chile, Colombia, Brazil and
Slide 10: Amaris Clinical - CRO Division of Caplin Point
Amaris Clinical - CRO Division of Caplin Point Highlights CRO division started for Captive BA/BE studies of own products, for LatAm, US and China. Cost per study reduces by around 50% Project cost at INR 25cr – internally LCMS-MS accrued. Sciex 4500+ : 2 72-bed state of the art facility. Sciex
Slide 11: Visionary Promoters & Experienced Management
Visionary Promoters & Experienced Management Mr. C.C.Paarthipan Dr. Sridhar Ganesan Dr. B. Philip Ashok Dr. K.C.John Mr. D.P. Mishra Chairman Managing Whole-time Independent Director Director Director Director 30+ Years of experience in the 35+ Years experience in 25+ Years of experience in th
Slide 12: Strongly Positioned to Deliver Robust Profitable Growth & Returns
Strongly Positioned to Deliver Robust Profitable Growth & Returns Significant growth in Return Ratios adds Revenue Tripled in the last 4 years Robustly growing EBITDA & PAT margins further impetus to the growth story Revenue (in Mn) 5,398 PAT Margin EBITDA Margin ROE ROCE 4,613 4,116 70% 71% 71% 70%
Slide 13: Financial Highlights – Q3 FY19
Financial Highlights – Q3 FY19 Revenue (INR Million) Q3FY19 Highlights 1,628 1,667 Xxx 1,439 1,463 1,481 Target to file 10 more ANDAs before Dec 19 • Taking the tally to 20 ANDAs filed from Caplin with 3 approvals already received Q3FY18 Q4FY18 Q1FY19 Q2FY19 Q3FY19 Moved injectable plant and o
Slide 14: Key Updates
Key Updates Expansion plans at Unit-1 in Pondicherry nearing completion, Five State of art R&D sites it includes addition of Injectable established, covering entire Preparation underway US FDA audit completed lines including Lyophilized spectrum of Dosage Forms to file products in China with Zero 48
Slide 15: “Capital Plus” partner for Caplin Steriles Ltd.
“Capital Plus” partner for Caplin Steriles Ltd. Proposed Transaction Structure Transaction Details Objective Increase R&D capabilities to include Complex Injectable and Ophthalmic products portfolio, and enhance capacities at Plant. Eight Roads and F-Prime Capital – Fidelity together bring acces
Slide 16: Growth Drivers
Growth Drivers Continuous capex investment of over INR 1.6 Bn over last 5 years towards enhanced manufacturing capabilities Progress underway for CRO wing of Caplin Point, a high margin End to end business model offering Quality, Price, Variety, segment of the industry, which would cover BE/BA studi
Slide 17: For further information, please contact
For further information, please contact: Company Investor Relations contact Christensen IR Vinod Kumar Dikshita Jain +91 44 24968119 022-42150210 investors@caplinpoint.net djain@christensenir.com 524742 CAPLIPOINT CAPL.NS © 2018 Caplin Point Laboratories Limited, All Rights Reserved. “Caplin Point”
Caplin Point Laboratories — Investor Presentation (February 2019) on 6ix